Tandem Diabetes Care Announces Succession Plan for Chief Executive Officer and Board of Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes Care (TNDM) PT Raised to $60 at Cowen Following 'Blowout'
February 27, 2019 8:31 AM ESTCowen analyst Doug Schenkel raised the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $60.00 (from $40.00) while maintaining a Outperform rating.
The analyst commented, "TNDM posted blowout top to bottom Q4 results. 2019 guidance was also materially ahead of consensus, and still... More
